A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

NCT01449058 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced and Selected Solid Tumors
AML
High Risk and Very High Risk MDS

Interventions

DRUG: BYL719
DRUG: MEK162

Sponsor

Array BioPharma